https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/
The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing MS
Create an account
or login to join the discussion